Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
7.13
+0.30 (4.39%)
At close: Dec 5, 2025, 4:00 PM EST
7.17
+0.04 (0.56%)
After-hours: Dec 5, 2025, 6:54 PM EST
ARCT Employees
As of December 31, 2024, Arcturus Therapeutics Holdings had 176 total employees, including 174 full-time and 2 part-time employees. The number of employees decreased by 4 or -2.22% compared to the previous year.
Employees
176
Change (1Y)
-4
Growth (1Y)
-2.22%
Revenue / Employee
$554,551
Profits / Employee
-$379,028
Market Cap
202.58M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARCT News
- 11 days ago - Arcturus Therapeutics to Attend Upcoming Investor Conference - Business Wire
- 25 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 5 weeks ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - Business Wire
- 6 weeks ago - Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture - Benzinga
- 6 weeks ago - Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results - Invezz
- 6 weeks ago - Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire